ChemGenex Pharmaceuticals to present updated clinical data from its clinical trials with Omapro

Dec 1 2009

ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today that updated clinical data from several of its clinical trials with Omapro™ (omacetaxine mepesuccinate) will be presented at the upcoming 51^st American Society of Hematology Annual Meeting in New Orleans, Louisiana.

Dr. Jorge Cortes, MD, Professor of Medicine and Deputy Chair in the Department of Leukemia at The University of Texas, MD Anderson Cancer Center will present data via oral presentations for both the ChemGenex studies 202 and 203.

On Monday, 7^th December at 4:45 p.m. Central Time, Dr. Cortes will present data from “Imatinib-Resistant Chronic Myeloid Leukemia (CML) Patients Who Harbor the Bcr-Abl T315I Mutation in an oral session entitled: Chronic Myeloid Leukemia - Therapy: Managing Resistance and Residual Disease.”

During the oral session entitled Chronic Myeloid Leukemia - Therapy: New Trends in Management, Dr. Cortes will present data from “CML Patients Who Are Resistant or Intolerant to Two or More Tyrosine Kinase Inhibitors.” This session will take place on Tuesday, 8^th December at 8:00 a.m. Central Time.

ChemGenex will also present combination data for Omapro during the poster session entitled: Chronic Myeloid Leukemia - Therapy on Sunday, December 6^th from 6:00 to 8:00 p.m. Central Time on Poster Board II-170. This phase 2 trial was designed to study the “Combination of Omacetaxine and Imatinib in the Treatment of Patients with CML in Advanced Stages or After Failure to Imatinib”.